Latest news
Oppenheimer Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $54 - MoomooMoomoo · Fri, 07 Aug 2026 19:42:39 GMTImmunovant, Inc. Q1 2027 Earnings Call Summary - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 21:51:11 GMTImmunovant Q1 Earnings Call Highlights - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 19:04:19 GMTImmunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside - TradingViewTradingView · Thu, 06 Aug 2026 17:20:18 GMTImmunovant's Q1 Loss Wider Than Expected, Pipeline in Progress - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 15:22:00 GMTImmunovant, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 13:32:01 GMTImmunovant Q1 net loss widens - TradingViewTradingView · Thu, 06 Aug 2026 11:31:22 GMTAug 06 (Reuters) - Immunovant Q1 Operating Ex - MoomooMoomoo · Thu, 06 Aug 2026 11:27:32 GMT